Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H20O9 |
Molecular Weight | 416.3781 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C2=C(O)C=CC3=C2OC=C(C3=O)C4=CC=C(O)C=C4
InChI
InChIKey=HKEAFJYKMMKDOR-VPRICQMDSA-N
InChI=1S/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2/t14-,17-,18+,19-,21+/m1/s1
Puerarin (7, 4’-dihydroxyisolavone-8-β-glucopyranoside) is an active isoflavone extracted from the roots of Pueraria lobata (Willd.) Ohwi. Puerarin is widely used in traditional Chinese medicine, and is clinically used in China for the treatment of coronary artery disease, heart failure, hypertension and myocardial infarction. It has been reported that puerarin had therapeutic effects on diabetes mellitus, arteriosclerosis and myocardial ischemia in animals. Puerarin demonstrated beta-adrenergic receptor blocking effect. On the other hand, puerarin stimulated alpha1-adrenoreceptor to increase glucose uptake into cultured C2C12 cells of mice. Puerarin has been investigated for the treatment (phase II clinical trials) of Alcohol Abuse, Rheumatoid Arthritis and Hypertension.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1914276 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21327545 |
|||
Target ID: Tetrodotoxin resistant (TTXr) sodium current Sources: https://www.ncbi.nlm.nih.gov/pubmed/9772657 |
|||
Target ID: P97718 Gene ID: 11549.0 Gene Symbol: Adra1a Target Organism: Mus musculus (Mouse) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12451490 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.07 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25264914 |
9.984 mg single, oral dose: 9.984 mg route of administration: Oral experiment type: SINGLE co-administered: |
PUERARIN blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
85.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25264914 |
9.984 mg single, oral dose: 9.984 mg route of administration: Oral experiment type: SINGLE co-administered: |
PUERARIN blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25264914 |
9.984 mg single, oral dose: 9.984 mg route of administration: Oral experiment type: SINGLE co-administered: |
PUERARIN blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Protective effects of puerarin on carbon tetrachloride-induced hepatotoxicity. | 2007 Oct |
|
Role of the interaction between puerarin and the erythrocyte membrane in puerarin-induced hemolysis. | 2011 Jul 15 |
|
Puerarin protects against lead-induced cytotoxicity in cultured primary rat proximal tubular cells. | 2014 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02254655
400 mg once a day. The treatment course consisted of 2 weeks followed by a 15-day interval for 24 weeks.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12451490
Radioactive glucose (2-DG) uptake was enhanced within 3 min of exposure to 10 uM/l puerarin. This action of puerarin increased gradually with longer incubation times to become half-maximal at 10 min and became maximally stimulated at 30 min.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
3581 (Number of products:1)
Created by
admin on Sat Dec 16 01:54:25 GMT 2023 , Edited by admin on Sat Dec 16 01:54:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID30958020
Created by
admin on Sat Dec 16 01:54:25 GMT 2023 , Edited by admin on Sat Dec 16 01:54:25 GMT 2023
|
PRIMARY | |||
|
5281807
Created by
admin on Sat Dec 16 01:54:25 GMT 2023 , Edited by admin on Sat Dec 16 01:54:25 GMT 2023
|
PRIMARY | |||
|
PUERARIN
Created by
admin on Sat Dec 16 01:54:25 GMT 2023 , Edited by admin on Sat Dec 16 01:54:25 GMT 2023
|
PRIMARY | |||
|
380711
Created by
admin on Sat Dec 16 01:54:25 GMT 2023 , Edited by admin on Sat Dec 16 01:54:25 GMT 2023
|
PRIMARY | |||
|
C033607
Created by
admin on Sat Dec 16 01:54:25 GMT 2023 , Edited by admin on Sat Dec 16 01:54:25 GMT 2023
|
PRIMARY | |||
|
Z9W8997416
Created by
admin on Sat Dec 16 01:54:25 GMT 2023 , Edited by admin on Sat Dec 16 01:54:25 GMT 2023
|
PRIMARY | |||
|
100000127786
Created by
admin on Sat Dec 16 01:54:25 GMT 2023 , Edited by admin on Sat Dec 16 01:54:25 GMT 2023
|
PRIMARY | |||
|
DB12290
Created by
admin on Sat Dec 16 01:54:25 GMT 2023 , Edited by admin on Sat Dec 16 01:54:25 GMT 2023
|
PRIMARY | |||
|
SUB33910
Created by
admin on Sat Dec 16 01:54:25 GMT 2023 , Edited by admin on Sat Dec 16 01:54:25 GMT 2023
|
PRIMARY | |||
|
3681-99-0
Created by
admin on Sat Dec 16 01:54:25 GMT 2023 , Edited by admin on Sat Dec 16 01:54:25 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD